2025 Q4 -tulosraportti
Vain PDF
66 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 26 168 | - | - | ||
| 300 | - | - | ||
| 3 521 | - | - | ||
| 506 | - | - | ||
| 636 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
·1 t sittenIt's fine to assess fair value in ordinary companies. P/E and P/B etc. But how to assess the value of Circio? It becomes much more difficult. The value is obviously what the market is willing to pay, but how to assess if the market "is wrong". Everyone understands that if we get a license agreement, the value will skyrocket. But what is fair value now. I have a friend named chatgpt.com. He thought the share issues with cash holdings contribute 1.5-2 kr per share. Risk-adjusted value of circvec based on study results 1.5-2.5 billion. Option value agreement with big pharma 0.5-1.5 billion. Fair value right now 11-12 kr. License agreement with BP with good upfront payment: 20 kr +. Take it for what it is. Have a good weekend. 😊
·29 min sitten · MuokattuI also asked about an acquisition price of kr 200 per share.: Yes, that is theoretically possible, but it requires a very special outcome. If there are around 238 million outstanding shares, an acquisition price of 200 kroner per share would correspond to a company value of approximately 47.6 billion kroner. To put that in perspective: * Today's market capitalization is around 2 billion kroner. * A bid of 200 kroner would be around 24 times higher than today's valuation. It is not impossible in biotechnology. Such acquisitions have occurred when a company possesses a technology that: * solves a major problem in drug development, * is protected by strong patents, * is validated by several large pharmaceutical companies, * and has shown clear results in humans or very convincing preclinical data. For Circio, several things would probably have to happen first: 1. Several large partnerships with global pharmaceutical companies. 2. Documentation that the circRNA-platform functions across several disease areas. 3. That the technology is perceived as a key platform, not just a single product. 4. Competition between several potential buyers. If all this happens, a premium of many tens of billions of kroner could become relevant. But with the information publicly known today, I believe that the probability of an acquisition at over 200 kroner per share is low. It would require the company to create significantly more value than the market currently prices in. At the same time, biotech is a sector with very skewed returns: many companies fail, while a few are acquired at many times their previous market capitalization. The question is whether Circio's technology develops into such a strategic platform. The next couple of years will probably provide a much clearer answer to that.
·1 t sittenSometimes I wonder why there's so much shit-slinging here on the forum🤔🤔🤔 Can't we just accept that we disagree and have different strategies for our investments without badmouthing others? It doesn't really affect me or you if someone holds, sells, or buys or whatever they might do...🤔 And thanks to those of you who actually contribute with facts here🙂 Wishing everyone a nice weekend and good luck with this and other stocks. I myself believe that Circio is a good investment and I'm staying in this one🙂 P.s I'm prepared for some 💩💩💩 on this post too😂
1 t sitten1 t sittenYou are absolutely right. I myself have faced some bad comments, when trying to bring some reason into the discussions. Circio might be a really good investment, but it might also fail. We all hope for the best, not just because we can make some money here and now, but also because this could save lifes in the future - that is my opinion the biggest goal.·43 min sittenIt's such a shame that those who actually have knowledge to contribute here perhaps just skip it because of all the nonsense and rubbish in the comment section. This is clearly a risk stock, but I hope and believe that those who buy shares know about the risk. But we all make mistakes sometimes, regardless of whether new or experienced in the stock world...🙈
·3 t sittenJust to have said it, I think some here need to be reminded that clinical studies take a very long time (years). That they require enormous capital, and not least that one can constantly be met with problems regarding tolerance and effect. Good luck!
·1 t sitten · Muokattu@gtrx09p you are absolutely right. I don't understand why you're getting so many harsh answers. It costs on average about 1 billion NOK to get a company into Phase 1, and that doesn't happen overnight, so to speak. Circio hasn't come into being overnight either. Targovax was established in 2010 and rebranded to Circio in 2023. They have already been at it for many years, and now we are starting to reap the fruits. Among other things, they have over 600 million kroner in liquid cash and have ongoing expensive studies fully financed by Big Pharma and other medium-sized and smaller specialized players. With its 600 million, Circio can easily get to Phase 1 because partners pay for the rest of the results and validation needed. Capital is no longer a problem for Circio, and they have world-leading researchers in their field. Circio are the pioneers in circRNA. Literally. Now the focus will be on research and further development at a pace we haven't seen the like of, because years of groundwork and strategic planning have been completed.
5 t sitten5 t sittenAs I said the other day, we are starting to see a rise in the share price. At this point, I would like to thank everyone who has purchased warrants, you did a valuable job for both the company and the investors. We have great news coming in June and in the form of a license agreement during the rest of the summer 🍺❤️ Let's enjoy the journey and take care of our assets 🍺 Happy Midsummer to everyone 🇫🇮
·5 t sitten · MuokattuRemember that Therorna has contributed some of the strongest data to date for circRNA CAN be used for the CAR-T concept, especially in vivo CAR-T, where T-cells are programmed directly in the body. What they don't have is Circio's vector technology, which we have all soon heard about. Higher expression/lower dose/better economics, longer half-life. Win/win. So of course Circio sweeps everything and everyone off the field, it's a bit of a 'no-brainer' I think. Q2 T-Cell delivery in vitro PoC. Not many days left. Buckle up your helmet, belt, and mother-in-law. 💰 All-in!·2 t sittenYes, that's smart, but I would just mess it up. I have bought 6200 shares in a separate account which I will try to trade a bit. Sell at some peaks, buy when the price dips. And if the train keeps going, that's fine. My main purchases at just over a krone will remain until an acquisition.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
66 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sittenIt's fine to assess fair value in ordinary companies. P/E and P/B etc. But how to assess the value of Circio? It becomes much more difficult. The value is obviously what the market is willing to pay, but how to assess if the market "is wrong". Everyone understands that if we get a license agreement, the value will skyrocket. But what is fair value now. I have a friend named chatgpt.com. He thought the share issues with cash holdings contribute 1.5-2 kr per share. Risk-adjusted value of circvec based on study results 1.5-2.5 billion. Option value agreement with big pharma 0.5-1.5 billion. Fair value right now 11-12 kr. License agreement with BP with good upfront payment: 20 kr +. Take it for what it is. Have a good weekend. 😊·29 min sitten · MuokattuI also asked about an acquisition price of kr 200 per share.: Yes, that is theoretically possible, but it requires a very special outcome. If there are around 238 million outstanding shares, an acquisition price of 200 kroner per share would correspond to a company value of approximately 47.6 billion kroner. To put that in perspective: * Today's market capitalization is around 2 billion kroner. * A bid of 200 kroner would be around 24 times higher than today's valuation. It is not impossible in biotechnology. Such acquisitions have occurred when a company possesses a technology that: * solves a major problem in drug development, * is protected by strong patents, * is validated by several large pharmaceutical companies, * and has shown clear results in humans or very convincing preclinical data. For Circio, several things would probably have to happen first: 1. Several large partnerships with global pharmaceutical companies. 2. Documentation that the circRNA-platform functions across several disease areas. 3. That the technology is perceived as a key platform, not just a single product. 4. Competition between several potential buyers. If all this happens, a premium of many tens of billions of kroner could become relevant. But with the information publicly known today, I believe that the probability of an acquisition at over 200 kroner per share is low. It would require the company to create significantly more value than the market currently prices in. At the same time, biotech is a sector with very skewed returns: many companies fail, while a few are acquired at many times their previous market capitalization. The question is whether Circio's technology develops into such a strategic platform. The next couple of years will probably provide a much clearer answer to that.
- ·1 t sittenSometimes I wonder why there's so much shit-slinging here on the forum🤔🤔🤔 Can't we just accept that we disagree and have different strategies for our investments without badmouthing others? It doesn't really affect me or you if someone holds, sells, or buys or whatever they might do...🤔 And thanks to those of you who actually contribute with facts here🙂 Wishing everyone a nice weekend and good luck with this and other stocks. I myself believe that Circio is a good investment and I'm staying in this one🙂 P.s I'm prepared for some 💩💩💩 on this post too😂1 t sitten1 t sittenYou are absolutely right. I myself have faced some bad comments, when trying to bring some reason into the discussions. Circio might be a really good investment, but it might also fail. We all hope for the best, not just because we can make some money here and now, but also because this could save lifes in the future - that is my opinion the biggest goal.·43 min sittenIt's such a shame that those who actually have knowledge to contribute here perhaps just skip it because of all the nonsense and rubbish in the comment section. This is clearly a risk stock, but I hope and believe that those who buy shares know about the risk. But we all make mistakes sometimes, regardless of whether new or experienced in the stock world...🙈
- ·3 t sittenJust to have said it, I think some here need to be reminded that clinical studies take a very long time (years). That they require enormous capital, and not least that one can constantly be met with problems regarding tolerance and effect. Good luck!·1 t sitten · Muokattu@gtrx09p you are absolutely right. I don't understand why you're getting so many harsh answers. It costs on average about 1 billion NOK to get a company into Phase 1, and that doesn't happen overnight, so to speak. Circio hasn't come into being overnight either. Targovax was established in 2010 and rebranded to Circio in 2023. They have already been at it for many years, and now we are starting to reap the fruits. Among other things, they have over 600 million kroner in liquid cash and have ongoing expensive studies fully financed by Big Pharma and other medium-sized and smaller specialized players. With its 600 million, Circio can easily get to Phase 1 because partners pay for the rest of the results and validation needed. Capital is no longer a problem for Circio, and they have world-leading researchers in their field. Circio are the pioneers in circRNA. Literally. Now the focus will be on research and further development at a pace we haven't seen the like of, because years of groundwork and strategic planning have been completed.
- 5 t sitten5 t sittenAs I said the other day, we are starting to see a rise in the share price. At this point, I would like to thank everyone who has purchased warrants, you did a valuable job for both the company and the investors. We have great news coming in June and in the form of a license agreement during the rest of the summer 🍺❤️ Let's enjoy the journey and take care of our assets 🍺 Happy Midsummer to everyone 🇫🇮
- ·5 t sitten · MuokattuRemember that Therorna has contributed some of the strongest data to date for circRNA CAN be used for the CAR-T concept, especially in vivo CAR-T, where T-cells are programmed directly in the body. What they don't have is Circio's vector technology, which we have all soon heard about. Higher expression/lower dose/better economics, longer half-life. Win/win. So of course Circio sweeps everything and everyone off the field, it's a bit of a 'no-brainer' I think. Q2 T-Cell delivery in vitro PoC. Not many days left. Buckle up your helmet, belt, and mother-in-law. 💰 All-in!·2 t sittenYes, that's smart, but I would just mess it up. I have bought 6200 shares in a separate account which I will try to trade a bit. Sell at some peaks, buy when the price dips. And if the train keeps going, that's fine. My main purchases at just over a krone will remain until an acquisition.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 26 168 | - | - | ||
| 300 | - | - | ||
| 3 521 | - | - | ||
| 506 | - | - | ||
| 636 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
66 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sittenIt's fine to assess fair value in ordinary companies. P/E and P/B etc. But how to assess the value of Circio? It becomes much more difficult. The value is obviously what the market is willing to pay, but how to assess if the market "is wrong". Everyone understands that if we get a license agreement, the value will skyrocket. But what is fair value now. I have a friend named chatgpt.com. He thought the share issues with cash holdings contribute 1.5-2 kr per share. Risk-adjusted value of circvec based on study results 1.5-2.5 billion. Option value agreement with big pharma 0.5-1.5 billion. Fair value right now 11-12 kr. License agreement with BP with good upfront payment: 20 kr +. Take it for what it is. Have a good weekend. 😊·29 min sitten · MuokattuI also asked about an acquisition price of kr 200 per share.: Yes, that is theoretically possible, but it requires a very special outcome. If there are around 238 million outstanding shares, an acquisition price of 200 kroner per share would correspond to a company value of approximately 47.6 billion kroner. To put that in perspective: * Today's market capitalization is around 2 billion kroner. * A bid of 200 kroner would be around 24 times higher than today's valuation. It is not impossible in biotechnology. Such acquisitions have occurred when a company possesses a technology that: * solves a major problem in drug development, * is protected by strong patents, * is validated by several large pharmaceutical companies, * and has shown clear results in humans or very convincing preclinical data. For Circio, several things would probably have to happen first: 1. Several large partnerships with global pharmaceutical companies. 2. Documentation that the circRNA-platform functions across several disease areas. 3. That the technology is perceived as a key platform, not just a single product. 4. Competition between several potential buyers. If all this happens, a premium of many tens of billions of kroner could become relevant. But with the information publicly known today, I believe that the probability of an acquisition at over 200 kroner per share is low. It would require the company to create significantly more value than the market currently prices in. At the same time, biotech is a sector with very skewed returns: many companies fail, while a few are acquired at many times their previous market capitalization. The question is whether Circio's technology develops into such a strategic platform. The next couple of years will probably provide a much clearer answer to that.
- ·1 t sittenSometimes I wonder why there's so much shit-slinging here on the forum🤔🤔🤔 Can't we just accept that we disagree and have different strategies for our investments without badmouthing others? It doesn't really affect me or you if someone holds, sells, or buys or whatever they might do...🤔 And thanks to those of you who actually contribute with facts here🙂 Wishing everyone a nice weekend and good luck with this and other stocks. I myself believe that Circio is a good investment and I'm staying in this one🙂 P.s I'm prepared for some 💩💩💩 on this post too😂1 t sitten1 t sittenYou are absolutely right. I myself have faced some bad comments, when trying to bring some reason into the discussions. Circio might be a really good investment, but it might also fail. We all hope for the best, not just because we can make some money here and now, but also because this could save lifes in the future - that is my opinion the biggest goal.·43 min sittenIt's such a shame that those who actually have knowledge to contribute here perhaps just skip it because of all the nonsense and rubbish in the comment section. This is clearly a risk stock, but I hope and believe that those who buy shares know about the risk. But we all make mistakes sometimes, regardless of whether new or experienced in the stock world...🙈
- ·3 t sittenJust to have said it, I think some here need to be reminded that clinical studies take a very long time (years). That they require enormous capital, and not least that one can constantly be met with problems regarding tolerance and effect. Good luck!·1 t sitten · Muokattu@gtrx09p you are absolutely right. I don't understand why you're getting so many harsh answers. It costs on average about 1 billion NOK to get a company into Phase 1, and that doesn't happen overnight, so to speak. Circio hasn't come into being overnight either. Targovax was established in 2010 and rebranded to Circio in 2023. They have already been at it for many years, and now we are starting to reap the fruits. Among other things, they have over 600 million kroner in liquid cash and have ongoing expensive studies fully financed by Big Pharma and other medium-sized and smaller specialized players. With its 600 million, Circio can easily get to Phase 1 because partners pay for the rest of the results and validation needed. Capital is no longer a problem for Circio, and they have world-leading researchers in their field. Circio are the pioneers in circRNA. Literally. Now the focus will be on research and further development at a pace we haven't seen the like of, because years of groundwork and strategic planning have been completed.
- 5 t sitten5 t sittenAs I said the other day, we are starting to see a rise in the share price. At this point, I would like to thank everyone who has purchased warrants, you did a valuable job for both the company and the investors. We have great news coming in June and in the form of a license agreement during the rest of the summer 🍺❤️ Let's enjoy the journey and take care of our assets 🍺 Happy Midsummer to everyone 🇫🇮
- ·5 t sitten · MuokattuRemember that Therorna has contributed some of the strongest data to date for circRNA CAN be used for the CAR-T concept, especially in vivo CAR-T, where T-cells are programmed directly in the body. What they don't have is Circio's vector technology, which we have all soon heard about. Higher expression/lower dose/better economics, longer half-life. Win/win. So of course Circio sweeps everything and everyone off the field, it's a bit of a 'no-brainer' I think. Q2 T-Cell delivery in vitro PoC. Not many days left. Buckle up your helmet, belt, and mother-in-law. 💰 All-in!·2 t sittenYes, that's smart, but I would just mess it up. I have bought 6200 shares in a separate account which I will try to trade a bit. Sell at some peaks, buy when the price dips. And if the train keeps going, that's fine. My main purchases at just over a krone will remain until an acquisition.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 26 168 | - | - | ||
| 300 | - | - | ||
| 3 521 | - | - | ||
| 506 | - | - | ||
| 636 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt